Laxatract 667 mg/ml oral solution

Laxatract is a veterinary medicinal product designed specifically for cats and dogs to treat constipation and facilitate bowel movements through its active ingredient, lactulose. The brand is part of Dechra Pharmaceuticals, a specialized global veterinary pharmaceuticals business. Originally established in the United Kingdom, Dechra has grown through significant acquisitions, including the purchase of the Dutch company Eurovet Animal Health in 2012, which originally developed and manufactured products like Laxatract.

Today, the product is primarily manufactured in the Netherlands at Dechra's specialized production facilities. In early 2024, Dechra Pharmaceuticals was acquired by the Swedish investment company EQT in partnership with the Abu Dhabi Investment Authority (ADIA), transitioning the company from a public listing on the London Stock Exchange to private ownership. Despite this shift in ownership, Dechra maintains its headquarters in Northwich, United Kingdom, and continues to operate as a leading global provider of animal healthcare solutions.